Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp in patients with type 2 diabetes

Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp in patients with type 2 diabetes - Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033511

Enrollment

Registered

2018-07-26

Start date

2017-08-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with type 2 diabetes treated with basal insulin and DPP-4 inhibitor. 2)HbA1c>7.5% 3)Patients who can respond to questionnaire survey. 4)Patients who gave written informed consent.

Exclusion criteria

Exclusion criteria: 1)Patients with severe renal dysfunction including patients requiring hemodialysis or peritoneal dialysis(eGFR<30ml/min). 2)pregnant 3)Patients who have severe diabetic ketosis, diabetic coma. 4)Patients with severe infection, severe injury or perioperative state.

Design outcomes

Primary

Measure	Time frame
The change in QOL scores from baseline to 3 months in patients with switched therapy to Liraglutide/IDegAsp.	—

Secondary

Measure	Time frame
Difference of change in HbA1c, body weight, units of insulin dose, frequency of hypoglycemia (SMBG), SD and CV % of FPG on SMBG, clinical and laboratory parameters	—

Countries

Japan

Contacts

Public ContactMarina Harada

Yokohama City University Medical Center Department of Endocrinology and Diabetes

onyogora@yokohama-cu.ac.jp045-261-5656

Outcome results